Soligenix, Inc. (SNGX) Financial Ratios
31 years of historical data (1995–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.39
↓-79% vs avg
5yr avg: 1.87
30Y Low1.1·High140.6
ROE
↓
-235.5%
↓+95% vs avg
5yr avg: -4959.1%
30Y Low-370%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SNGX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Soligenix, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $7M | $4M | $6M | $19M | $29M | $35M | $28M | $11M | $14M | $8M |
| Enterprise Value | $-3468731 | $-625018 | $-1852779 | $925112 | $16M | $13M | $27M | $23M | $2M | $6M | $-709287 |
| P/E Ratio → | -0.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 77.87 | 882.83 | 18.22 | 8.74 | 2.16 | 2.51 | 0.77 |
| P/B Ratio | 0.39 | 1.31 | 1.09 | 2.33 | — | 2.75 | 9.40 | 19.28 | 1.80 | 2.16 | 1.09 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SNGX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 65.39 | 400.64 | 13.99 | 7.09 | 0.45 | 1.07 | -0.07 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SNGX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -235.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -120.3% | -2084.8% | 5.7% | -10.9% | 12.3% | 20.7% | 19.3% |
| Operating Margin | — | — | — | — | -5695.6% | -39276.1% | -962.8% | -327.8% | -172.8% | -139.8% | -54.6% |
| Net Profit Margin | — | — | — | — | -5519.3% | -37633.0% | -916.3% | -290.9% | -169.8% | -131.6% | -31.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -235.5% | -235.5% | -249.0% | -23803.1% | -334.4% | -173.5% | -680.5% | -241.8% | -141.3% | -104.2% | -88.0% |
| ROA | -121.7% | -121.7% | -88.1% | -51.0% | -67.1% | -53.7% | -127.9% | -102.4% | -88.8% | -72.1% | -36.8% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -245.4% | -245.4% | -243.2% | -1093.4% | -155.3% | -76.2% | -243.4% | -272.3% | -143.8% | -110.7% | -154.8% |
SNGX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $8M exceeds total debt of $358144, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.36 | 1.39 | — | 0.93 | 2.81 | 0.09 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.43 | -1.54 | -1.96 | — | -1.50 | -2.18 | -3.63 | -1.43 | -1.24 | -1.19 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -156.20 | -17.18 | -13.83 | -1701.39 | — | — | — | — |
Net cash position: cash ($8M) exceeds total debt ($358144)
SNGX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Soligenix, Inc.'s current ratio of 2.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.55x to 2.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | 2.39 | 1.82 | 1.55 | 0.84 | 4.22 | 3.20 | 1.19 | 2.46 | 2.92 | 3.52 |
| Quick Ratio | 2.39 | 2.39 | 1.82 | 1.55 | 0.84 | 4.22 | 3.20 | 1.19 | 2.46 | 2.92 | 3.52 |
| Cash Ratio | 2.15 | 2.15 | 1.61 | 1.37 | 0.81 | 4.14 | 3.07 | 0.86 | 2.13 | 2.42 | 3.06 |
| Asset Turnover | — | — | — | — | 0.02 | 0.00 | 0.10 | 0.41 | 0.50 | 0.57 | 1.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 320.22 | 2656.39 | 106.80 | 166.05 | 83.69 | 90.25 | 42.15 |
SNGX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Soligenix, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $2M | $484877 | $179459 | $185797 | $114529 | $80735 | $54909 | $25601 | $14932 |
Peer Comparison
Compare SNGX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SNGXYou | $4M | -0.2 | — | — | — | — | -235.5% | — | — |
 XTLB | $297068 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 ADXN | $5M | -0.8 | — | — | 100.0% | -9390.8% | -93.2% | -44.3% | — |
 NUVB | $2B | -9.6 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 HALO | $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 AGEN | $127M | -894.1 | — | — | 29.6% | -18.0% | — | — | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 TGTX | $8B | 19.6 | 68.9 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 CRL | $9B | -62.4 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MEDP | $13B | 29.8 | 22.7 | 19.1 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SNGX — Frequently Asked Questions
Quick answers to the most common questions about buying SNGX stock.
What is Soligenix, Inc.'s P/E ratio?
Soligenix, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Soligenix, Inc.'s ROE?
Soligenix, Inc.'s return on equity (ROE) is -235.5%. The historical average is -147.8%.
Is SNGX stock overvalued?
Based on historical data, Soligenix, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.